Afaxys announces wider US availability of ella emergency contraceptive

12 November 2014

US drugmaker Afaxys Pharmaceuticals, a division of Afaxys Inc, has announced wider US availability of ella (ulipristal acetate), a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure.

The controversial emergency contraceptive product, which prompted an outcry from the Family Research Council - which branded the drug as an abortifacient, was developed by French company HRA Pharma, which gained US Food and Drug Administration approval for ella in 2010 (The Pharma Letter August 16, 2010).

“ella is a first-of-its-kind product that offers a proven method to help prevent pregnancy before it starts. It’s exciting that this new generation emergency contraceptive with proven safety and tolerability in over 1.4 million women in Europe is now available to US women,” said Cheryl Gibson, medical director for Afaxys.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK